FluidAI Medical announces an acquisition deal with Emmetros Limited
FluidAI announces the acquisition of Emmetros, enhancing patient engagement with Stream Inara™ and innovative AI solutions.
A Tumor-Driven vaccine by Esphera SynBio is accelerating in vivo therapies
A recap of the September Hamilton Health Innovation Check-up with Esphera SynBio, sharing their journey, updates, and what’s next.
Researchers discover new antibiotic for IBD and AI correctly predicts how it works
Learn how researchers from Stoked Bio are discovering new antibiotics for IBD using AI-based drug discovery solutions.
How Stoked Bio is Using AI to Fight Deadly Diseases
Learn how Stoked Bio, an AI-based drug discovery startup, is leveraging key resources and support from the ecosystem.
FluidAI secures a $2-million Government of Canada investment to accelerate global commercialization of AI-driven postoperative care technology
FluidAI Medical has secured an investment of $2 million from the Government of Canada to enhance its AI-driven postoperative care technology.
13171229 B.C. Ltd. and Launchit Solutions Inc. Announce Execution of Business Combination Agreement and Launchit’s Concurrent Financing
Launchit Solutions enters business combination with 13171229 B.C. Ltd., to become a public traded company, enhancing capital access and market presence.
iGan Partners leads Seed+ financing for Cosm Medical to advance personalized gynecological devices
Cosm Medical, backed by iGan Partners, is set to advance personalized pelvic health with AI-driven, 3D-printed Gynethotics™ device.
Canadian innovation revolutionizes menstrual health worldwide with the Bfree Cup – The world’s first boil-free, antibacterial menstrual cup
The Bfree Cup is a game-changing antibacterial menstrual cup that promotes gender equity and combats period poverty.
FluidAI leading the way in AI-driven post-operative care
Learn how FluidAI is revolutionizing patient outcomes with AI-powered post-operative care and support for recovery.
University spin-out Afynia secures $5M seed to commercialize its microRNA panel test for endometriosis
Discover how Afynia Laboratories secured a $5 million seed round to commercialize its microRNA panel test for endometriosis.